TSC2 and tuberous sclerosis: Recent studies in TSC that employed either human embryonic stem cell lines with heterozygous or homozygous loss of TSC2 or TSC patient iPSC-derived neurons with heterozygous loss of TSC2 confirmed that mTORC1 inhibition corrects synaptic defects [22, 25].